The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index; 4 of the 8 sources its claims cite were checked for support.
A prudent path forward for genomic engineering and germline gene modification
Open accessAbstract
A framework for open discourse on the use of CRISPR-Cas9 technology to manipulate the human genome is urgently needed , Genome engineering technology offers unparalleled potential for modifying human and nonhuman genomes. In humans, it holds the promise of curing genetic disease, while in other organisms it provides methods to reshape the biosphere for the benefit of the environment and human societies. However, with such enormous opportunities come unknown risks to human health and well-being. In January, a group of interested stakeholders met in Napa, California ( 1 ), to discuss the scientific, medical, legal, and ethical implications of these new prospects for genome biology. The goal was to initiate an informed discussion of the uses of genome engineering technology, and to identify those areas where action is essential to prepare for future developments. The meeting identified immediate steps to take toward ensuring that the application of genome engineering technology is performed safely and ethically.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
A 2015 Science policy forum from the Napa meeting argues that CRISPR-Cas9 genome engineering offers major promise but also unknown risks, especially for human germline modification. It recommends broad open discussion and, in the near term, strongly discouraging clinical human germline genome modification while research and governance proceed.
Key findings
- The Napa meeting concluded there is an urgent need for open discussion of the merits and risks of human genome modification by a broad cohort including scientists, clinicians, social scientists, the general public, and relevant public entities and interest groups.
- Near-term recommendations include strongly discouraging germline genome modification for clinical application in humans, even in lax jurisdictions; creating expert forums for education; encouraging transparent research on efficacy and specificity in human and nonhuman model systems; and convening a globally representative group to consider policies.
- The paper notes that human germline engineering methods have already been demonstrated in mice and monkeys, and it distinguishes mitochondrial transfer—which does not use CRISPR-Cas9 and was approved by the Human Fertilisation and Embryology Authority and by Parliament in the United Kingdom—from nuclear germline editing.
- No quantitative data or effect sizes are reported; the text is a consensus policy commentary.
Methods
- Design: policy forum/commentary reporting on a January 2015 Napa, California meeting of CRISPR-Cas9 developers and users and experts in genetics, law, and bioethics; all participants were from the United States.
- Data or sample: no empirical dataset; discussion focused on human germline engineering and did not address mitochondrial transfer.
- Main analysis: consensus discussion and recommendations for governance, risk assessment, public engagement, and research priorities.
Limitations
- Stated: the Napa discussion did not address mitochondrial transfer; the group was all from the United States, and the paper calls for globally representative participation.
- Stated: limits to knowledge of human genetics, gene-environment interactions, and disease pathways create uncertainty about unintended consequences of heritable germline modifications.
- Evident from the text: the recommendations are not based on systematic data or quantitative risk assessment and are advisory rather than binding.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 of 8 cited sources checked · 3 supported · 0 flagged · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“focused on the issue of human germline engineering, as the methods have already been demonstrated in mice (6) and monkeys (7).”
§ A prudent path forward for genomic engineering and germline gene modification > MOVING FORWARD
What the sources say
- Supportedcites [6] Wang H Cell 2013 153 910 Medline 23643243 PMC3969854 source
The Introduction states that the authors use CRISPR/Cas to edit multiple genes in stem cells and mice, and the Discussion reports generating mice with multiple genetic alterations. This source supports the mice portion of the citing sentence; the monkeys portion is assigned to a separate citation. (LLM, conf=0.93)
- Supportedcites [7] Niu Y Cell 2014 156 836 Medline 24486104 source
The citation to this paper supports the monkey part of the sentence. The Summary reports CRISPR/Cas9 gene targeting in one-cell-stage cynomolgus monkey embryos and the generation of gene-modified monkeys; the mice citation is separate. (LLM, conf=0.93)
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The technique also allows DNA sequence changes in pluripotent embryonic stem cells (4) that can then be cultured to produce specific tissues, such as cardiomyocytes or neurons (5).”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
What the sources say
- Partly supportedcites [4] Mali P Science 2013 339 823 Medline 23287722 PMC3712628 sourceExperimental — accuracy not yet measured
The paper’s genome-targeting results report CRISPR-Cas9 editing in human induced pluripotent stem (iPS) cells, supporting the claim that the technique can change DNA in pluripotent cells. It does not report editing embryonic stem cells; the citing sentence attaches this source to that part, while assigning the tissue-differentiation claim to citation (5). (LLM, conf=0.88)
- Supportedcites [5] Zhu Z González F Huangfu D Methods Enzymol 2014 546 215 Medline 25398343 PMC4418970 source
Citation (4) is attached to the claim that CRISPR-Cas9 allows DNA sequence changes in pluripotent embryonic stem cells, not to the later examples of cardiomyocytes or neurons. The Introduction identifies human embryonic stem cells as human pluripotent stem cells and describes CRISPR/Cas genome editing in those cells; Section 2 reports highly efficient editing at target loci. (LLM, conf=0.93)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
In the paper
“Although characterized by some as another form of “germline” engineering, mitochondrial transfer raises different issues and has already been approved by the Human Fertilisation and Embryology Authority and by Parliament in the United Kingdom (10) and is being considered by the Institute of Medicine and the Food and Drug Administration in the United States (11).”
§ A prudent path forward for genomic engineering and germline gene modification > MOVING FORWARD
What the sources say
- Not matchedcites [11] U.S. Food and Drug Administration, Cellular, Tissue, and Gene Therapies Advisory Committee Meeting: Announcement www.fda.gov/AdvisoryCommittees/Calendar/ucm380042.htm; www.iom.edu/activities/research/mitoethics.aspx.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Humans are no exception—changes to the human germ line could be made using this simple and widely available technology.”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: CRISPR-Cas9 and other genome engineering methods can be used to change DNA in the nuclei of reproductive cells (germ line).
In the paper
“For example, the CRISPR-Cas9 system enables introduction of DNA sequence changes that correct genetic defects in whole animals, such as replacing a mutated gene underlying liver-based metabolic disease in a mouse model (3).”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
What the sources say
- Not checked yetcites [3] Yin H Nat. Biotechnol 2014 32 551 Medline 24681508 PMC4157757 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Even this seemingly straightforward scenario raises serious concerns, including the potential for unintended consequences of heritable germline modifications,”
§ A prudent path forward for genomic engineering and germline gene modification > MOVING FORWARD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: There are limits to current knowledge of human genetics, gene-environment interactions, and disease pathways.
- Probably not a substantial claim. 2
- It may state two separate claims as one. 3
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Such studies are laying the groundwork for refined approaches that could eventually treat human disease.”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
In the paper
“Although characterized by some as another form of “germline” engineering, mitochondrial transfer raises different issues and has already been approved by the Human Fertilisation and Embryology Authority and by Parliament in the United Kingdom (10) and is being considered by the Institute of Medicine and the Food and Drug Administration in the United States (11).”
§ A prudent path forward for genomic engineering and germline gene modification > MOVING FORWARD
What the sources say
- Not checked yetcites [10] The Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015 www.legislation.gov.uk/uksi/2015/572/contents/made (effective 29 October 2015).
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“However, this limitation has been upended by the rapid development and widespread adoption of a simple, inexpensive, and remarkably effective genome engineering method known as clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 (2).”
§ A prudent path forward for genomic engineering and germline gene modification > Abstract
What the sources say
- Not matchedcites [2] Doudna JA Charpentier E Science 2014 346 1258096 Medline 25430774
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The simplicity of the CRISPR-Cas9 system allows any researcher with knowledge of molecular biology to modify genomes, making feasible experiments that were previously difficult or impossible to conduct.”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, it is now possible to carry out genome modification in fertilized animal eggs or embryos, thereby altering the genetic makeup of every differentiated cell in an organism and so ensuring that the changes will be passed on to the organism’s progeny.”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
- Rests on an assumption: CRISPR-Cas9 and other genome engineering methods can be used to change DNA in the nuclei of reproductive cells (germ line).
The paper relies on this without support.
There are limits to current knowledge of human genetics, gene-environment interactions, and disease pathways.
“because there are limits to our knowledge of human genetics, gene-environment interactions, and the pathways of disease (including the interplay between one disease and other conditions or diseases in the same patient).”
The paper relies on this without support.
In the United States, human research involving heritable germline modifications currently would require an Investigational New Drug exemption from the FDA.
“In the United States, such human research currently would require an Investigational New Drug exemption from the Food and Drug Administration”
The paper relies on this without support.
In countries with a highly developed bioscience capacity, germline genome modification in humans is currently illegal or tightly regulated.
“(In countries with a highly developed bioscience capacity, germline genome modification in humans is currently illegal or tightly regulated.)”
The paper relies on this without support.
Mitochondrial transfer does not use CRISPR-Cas9.
“The Napa discussion did not address mitochondrial transfer (8, 9), a technique that does not use CRISPR-Cas9.”
The paper relies on this without support.
Public trust in science ultimately begins with and requires ongoing transparency and open discussion.
“At the dawn of the recombinant DNA era, the most important lesson learned was that public trust in science ultimately begins with and requires ongoing transparency and open discussion.”
The paper relies on this without support.
CRISPR-Cas9 and other genome engineering methods can be used to change DNA in the nuclei of reproductive cells (germ line).
“In addition to facilitating changes in differentiated somatic cells of animals and plants, CRISPR-Cas9 technology as well as other genome engineering methods can be used to change the DNA in the nuclei of reproductive cells that transmit information from one generation to the next (an organism’s “germ line”).”
The paper relies on this without support.
Off-target alterations and on-target events with unintended consequences are possible with CRISPR-Cas9.
“Considerations include the possibility of off-target alterations, as well as on-target events that have unintended consequences.”
The authors state this as an assumption.
The safety and efficacy of genome engineering technology can be ensured.
“Assuming the safety and efficacy of the technology can be ensured, a key point of discussion is whether the treatment or cure of severe diseases in humans would be a responsible use of genome engineering, and if so, under what circumstances.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subsequent report of the results of the conference was published in March 2015 in the journal Science [46], which essentially carried recommendations to strongly discourage work on introducing heritable changes in human embryonic cells, at least for the duration of active discussions of the social, environmental and ethical consequences of such manipulations.”
From CRISPR–Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing (2022) · cites this paper as [46]
Citations
Cites
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Self-citationThe new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Self-citationWang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Niu, Y., Shen, B., Cui, Y., Chen, Y., Wang, J., Wang, L., Kang, Y., Zhao, X., Si, W., Li, W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.027 · Cited by 1,033
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
Towards germline gene therapy of inherited mitochondrial diseases
Tachibana, M., Amato, P., Sparman, M. L., Woodward, J., Melguizo‐Sanchis, D., Ma, H., Gutiérrez, N. M., Tippner-Hedges, R., Kang, E., Lee, H.-S., et al. (2012) · Nature · doi:10.1038/nature11647 · Cited by 429
The iCRISPR Platform for Rapid Genome Editing in Human Pluripotent Stem Cells
Zhu, Z., González, F., & Huangfu, D. (2014) · Methods in Enzymology · doi:10.1016/b978-0-12-801185-0.00011-8 · Cited by 66
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 733
Gene Editing, Enhancing and Women’s Role
Simonstein, F. (2019) · Science and Engineering Ethics · doi:10.1007/s11948-017-9875-5 · Cited by 11
Human Embryo Editing: Opportunities and Importance of Transnational Cooperation
Pei, D., Beier, D. W., Levy‐Lahad, E., Marchant, G. E., Rossant, J., Belmonte, J. C. I., Lovell-Badge, R. H., Jaenisch, R., Charo, A., & Baltimore, D. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.09.010 · Cited by 21
Self-citationGregg, B. (2022) · The Journal of Medicine and Philosophy A Forum for Bioethics and Philosophy of Medicine · doi:10.1093/jmp/jhac008 · Cited by 21
Howell, E. L., Yang, S., Beets, B., Brossard, D., Scheufele, D. A., & Xenos, M. A. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0004 · Cited by 21
The discovery and development of the CRISPR system in applications in genome manipulation
Lau, V., & Davie, J. (2016) · Biochemistry and Cell Biology · doi:10.1139/bcb-2016-0159 · Cited by 21
Gene Editing in Clinical Practice: Where are We?
Mittal, R. D. (2019) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-018-0804-4 · Cited by 21
Modification of the Embryo's Genome: More Useful in Research Than in the Clinic
Mertes, H., & Pennings, G. (2015) · The American Journal of Bioethics · doi:10.1080/15265161.2015.1103813 · Cited by 21
Guiding Ethical Principles in Engineering Biology Research
Mackelprang, R., Aurand, E. R., Bovenberg, R. A. L., Brink, K. R., Charo, R. A., Delborne, J., Diggans, J., Ellington, A. D., Fortman, J. L., Isaacs, F. J., et al. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00129 · Cited by 21
Self-citationGenome editing in pluripotent stem cells: research and therapeutic applications
Deleidi, M., & Yu, C. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.02.113 · Cited by 20
The Synthetic Nature of Biology
Acevedo‐Rocha, C. G. (2015) · Ethics of science and technology assessment/Wissenschaftsethik und Technikfolgenbeurteilung · doi:10.1007/978-3-319-21088-9_2 · Cited by 20
CRISPR-based biosensor for the detection of Marburg and Ebola virus
Irkham, I., Ibrahim, A. U., Pwavodi, P. C., Nwekwo, C. W., & Hartati, Y. W. (2023) · Sensing and Bio-Sensing Research · doi:10.1016/j.sbsr.2023.100601 · Cited by 20
Where Will We Draw the Line? Public Opinions of Human Gene Editing
Riggan, K. A., Sharp, R. R., & Allyse, M. A. (2019) · Qualitative Health Research · doi:10.1177/1049732319846867 · Cited by 20
Initial heritable genome editing: mapping a responsible pathway from basic research to the clinic
Ranisch, R., Trettenbach, K., & Arnason, G. (2023) · Medicine, Health Care and Philosophy · doi:10.1007/s11019-022-10115-x · Cited by 19
Gene editing and CRISPR-dependent homology-mediated end joining
Ruis, B. L., Bielinsky, A., & Hendrickson, E. A. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01442-z · Cited by 20
Responsible governance of human germline genome editing in China
Peng, Y., Lv, J., Ding, L., Gong, X., & Zhou, Q. (2022) · Biology of Reproduction · doi:10.1093/biolre/ioac114 · Cited by 19
Kozubek, J. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781316771440 · Cited by 19
CRISPR/Cas faces the bioethics spotlight
Perkel, J. M. (2015) · BioTechniques · doi:10.2144/000114284 · Cited by 18
Khan, M. S. (2023) · AI and Ethics · doi:10.1007/s43681-023-00360-y · Cited by 18
Ethical issues in human germline gene editing: a perspective from China
Zhang, D., & Lie, R. K. (2018) · Bioethics News · doi:10.1007/s40592-018-0091-0 · Cited by 18
A Practical Guide to Genome Editing Using Targeted Nuclease Technologies
Porter, S. N., Levine, R. M., & Pruett‐Miller, S. M. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180022 · Cited by 18
Why Include the Public in Genome Editing Governance Deliberation?
Blasimme, A. (2019) · The AMA Journal of Ethic · doi:10.1001/amajethics.2019.1065 · Cited by 18
Al-Balas, Q. A., Dajani, R. B., & Al‐Delaimy, W. K. (2020) · Science and Engineering Ethics · doi:10.1007/s11948-020-00205-5 · Cited by 18
Gene Therapy and Gene Editing for the Corneal Dystrophies
Williams, K. A., & Irani, Y. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000215 · Cited by 18
Genome editing and international regulatory challenges: Lessons from Mexico
Chan, S., & Arellano, M. D. J. M. (2016) · Ethics Medicine and Public Health · doi:10.1016/j.jemep.2016.05.001 · Cited by 18
The CRISPR Growth Spurt: from Bench to Clinic on Versatile Small RNAs
Bayat, H., Omidi, M., Rajabibazl, M., Sabri, S., & Rahimpour, A. (2017) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1607.07005 · Cited by 18
When is it Safe to Edit the Human Germline?
Baxter, J. K. (2021) · Science and Engineering Ethics · doi:10.1007/s11948-021-00320-x · Cited by 17
When does precision matter? Personalized medicine from the perspective of public health
Wilson, J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0013 · Cited by 17
Liu, J., Kang, D.-L., Mi, P., Xu, C., Zhu, L. Q., & Wei, B. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00902 · Cited by 17
Computational Prediction of Protein Complexes from Protein Interaction Networks
Srihari, S., Yong, C. H., & Wong, L. (2017) · doi:10.1145/3064650 · Cited by 17
Greely, H. T. (2017) · The Hastings Center Report · doi:10.1002/hast.749 · Cited by 17
Self-citationvan Dijke, I., van Wely, M., Berkman, B. E., Bredenoord, A. L., Henneman, L., Vliegenthart, R., Repping, S., & Hendriks, S. (2020) · Human Reproduction · doi:10.1093/humrep/deaa212 · Cited by 17
The role of scientific self‐regulation for the control of genome editing in the human germline
Gregorowius, D., Biller‐Andorno, N., & Deplazes‐Zemp, A. (2017) · EMBO Reports · doi:10.15252/embr.201643054 · Cited by 17
Macintosh, K. L. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108557818 · Cited by 17
Justice, Equity, Diversity, and Inclusion Curriculum Within an Introductory Bioengineering Course
Shields, B. (2022) · Biomedical Engineering Education · doi:10.1007/s43683-022-00086-z · Cited by 16
Campbell, M., & McNamee, M. (2020) · Sport Ethics and Philosophy · doi:10.1080/17511321.2020.1737204 · Cited by 16
The biological feasibility and social context of gene-edited, caffeine-free coffee
Leibrock, N., Santegoets, J., Mooijman, P. J. W., Yusuf, F., Zuijdgeest, X. C. L., Zutt, E. A., Jacobs, J. G. M., & Schaart, J. G. (2022) · Food Science and Biotechnology · doi:10.1007/s10068-022-01082-3 · Cited by 16
Developmental history and application of CRISPR in human disease
Liang, P., Zhang, X., Chen, Y., & Huang, J. (2017) · The Journal of Gene Medicine · doi:10.1002/jgm.2963 · Cited by 16
Dealing With Rejection: An Application of the Exit–Voice Framework to Genome-Edited Food
Bartkowski, B., & Baum, C. M. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00057 · Cited by 16
Benston, S. (2016) · Laws · doi:10.3390/laws5010005 · Cited by 16
Governance of Heritable Human Gene Editing World-Wide and Beyond
Xue, Y., & Shang, L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19116739 · Cited by 16
Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies
Bauer, D. E., Brendel, C., & Fitzhugh, C. D. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.08.014 · Cited by 15
CRISPR as agent: a metaphor that rhetorically inhibits the prospects for responsible research
Ceccarelli, L. (2018) · Life Sciences Society and Policy · doi:10.1186/s40504-018-0088-8 · Cited by 15
Howell, E. L., Kohl, P. A., Scheufele, D. A., Clifford, S., Shao, A., Xenos, M. A., & Brossard, D. (2020) · Journal of Risk Research · doi:10.1080/13669877.2020.1806911 · Cited by 15
Ethical and regulatory issues in human gene editing: Chinese perspective
Lei, R., & Renzong, Q. (2020) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2032 · Cited by 15
The ethics of publishing human germline research
Sharma, A., & Scott, C. T. (2015) · Nature Biotechnology · doi:10.1038/nbt.3252 · Cited by 15
Advena-Regnery, B., Dederer, H., Enghofer, F., Cantz, T., & Heinemann, T. (2018) · Bioethics · doi:10.1111/bioe.12433 · Cited by 15
Rose, B. I., & Brown, S. (2019) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003327 · Cited by 15
Role of Modern Technologies in Tissue Engineering
Ali, Q., Malik, S., Malik, A., Hafeez, M. N., & Salman, S. (2020) · Archives of Neuroscience · doi:10.5812/ans.90394 · Cited by 15
The CRISPR Revolution in Genome Engineering: Perspectives from Religious Ethics
Lee, J. (2022) · Journal of Religious Ethics · doi:10.1111/jore.12402 · Cited by 14
Risk and Responsibility in Context
Placani, A., & Broadhead, S. (2023) · Routledge eBooks · doi:10.4324/9781003276029 · Cited by 14
Neurotechnological Convergence and “Big Data”: A Force-Multiplier Toward Advancing Neuroscience
DiEuliis, D., & Giordano, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-28422-4_6 · Cited by 14
A short, idiosyncratic history of genome editing
Carroll, D. (2021) · Gene and Genome Editing · doi:10.1016/j.ggedit.2021.100002 · Cited by 14
Self-citationCRISPR as a driving force: the Model T of biotechnology
Mariscal, C., & Petropanagos, A. (2016) · Bioethics News · doi:10.1007/s40592-016-0062-2 · Cited by 14
Gene editing of stem cells for kidney disease modelling and therapeutic intervention
Lau, R. W., Wang, B., & Ricardo, S. D. (2018) · Nephrology · doi:10.1111/nep.13410 · Cited by 14
Benston, S. (2017) · Journal of Medical Ethics · doi:10.1136/medethics-2016-103666 · Cited by 14
Ethics in Biomedical Animal Research: The Key Role of the Investigator a
Tannenbaum, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00001-2 · Cited by 14
Future Technological Achievements as a Challenge for Post-singularity Human Society
Цирель, С. В. (2020) · World-systems evolution and global futures · doi:10.1007/978-3-030-33730-8_19 · Cited by 13
Serra, M.-À. (2021) · Mètode: Revista de difusió de la investigació de la Universitat de Valencia · doi:10.7203/metode.12.20676 · Cited by 13
Shabana, A. (2022) · Journal of Religious Ethics · doi:10.1111/jore.12404 · Cited by 13
Access to CRISPR Genome Editing Technologies: Patents, Human Rights and the Public Interest
Matthews, D. (2021) · Springer eBooks · doi:10.1007/978-3-030-83114-1_4 · Cited by 13
Novaes, H. M. D., & de Soárez, P. C. (2019) · Sociologias · doi:10.1590/15174522-0215121 · Cited by 13
Responsible Translational Pathways for Germline Gene Editing?
Cwik, B. (2020) · Current Stem Cell Reports · doi:10.1007/s40778-020-00179-x · Cited by 13
CRISPR: a journey of gene-editing based medicine
Golkar, Z. (2020) · Genes & Genomics · doi:10.1007/s13258-020-01002-x · Cited by 13
Taking responsibility, making irresponsibility: Controversies in human gene editing
Meyer, M. (2021) · Social Studies of Science · doi:10.1177/03063127211025631 · Cited by 13
Efficient base editing and development in human embryos without chromosomal alterationsPreprint
Jerabek, S., Kim, J., Sung, J., Jung, C., Kulmann, M. I. R., Isado, M., Jang, H.-S., Li, M., Bhatele, S., Kappy, M. D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.30.728989 · Cited by 13
Banerjee, D., Bhattacharya, A., Puri, A. V., Munde, S. V., Mukerjee, N., Mohite, P. B., Kazmi, S. W., Sharma, A., Alqahtani, T., & Shmrany, H. A. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002111 · Cited by 12
Debating Ethical Issues in Genome Editing Technology
Renzong, Q. (2016) · Asian Bioethics Review · doi:10.1353/asb.2016.0026 · Cited by 12
Kipke, R., Rothhaar, M., & Hähnel, M. (2017) · Ethik in der Medizin · doi:10.1007/s00481-017-0435-y · Cited by 12
Greenfield, A. (2018) · British Medical Bulletin · doi:10.1093/bmb/ldy020 · Cited by 12
Wäscher, S., Biller‐Andorno, N., & Deplazes‐Zemp, A. (2020) · NanoEthics · doi:10.1007/s11569-020-00365-5 · Cited by 12
Replicating and Cycling Stores of Information Perpetuate Life
Jose, A. M. (2018) · BioEssays · doi:10.1002/bies.201700161 · Cited by 12
Meyer, M., & Heimstädt, C. (2019) · Plant Biotechnology Reports · doi:10.1007/s11816-019-00578-5 · Cited by 12
Editing the Genome of the Human Germline: May Cool Heads Prevail
Adashi, E. Y., & Cohen, I. G. (2015) · The American Journal of Bioethics · doi:10.1080/15265161.2015.1103805 · Cited by 12
Mammalian genome writing: Unlocking new length scales for genome engineering
Pinglay, S., Atwater, J. T., Brosh, R., Shendure, J., Maurano, M. T., & Boeke, J. D. (2026) · Cell · doi:10.1016/j.cell.2025.12.034 · Cited by 11
Thérapie génique germinale, le retour ?
Jordan, B. (2015) · médecine/sciences · doi:10.1051/medsci/20153106025 · Cited by 11
Lyu, Y., Yin, M., Xi, F., & Hu, X. (2022) · Journal of Data and Information Science · doi:10.2478/jdis-2022-0004 · Cited by 11
The advent of automated medicine? The values and meanings of precision
Prainsack, B. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0015 · Cited by 11
“I bet you won't”: The science–society wager on gene editing techniques
Braun, M., & Dabrock, P. (2016) · EMBO Reports · doi:10.15252/embr.201541935 · Cited by 11
Unlocking the potential of CRISPR technology for improving livelihoods in Africa
Mudziwapasi, R., Ndudzo, A., Nyamusamba, R. P., Jomane, F. N., Mutengwa, T. T., & Maphosa, M. (2018) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2018.1482101 · Cited by 11
Editing the Reactive Genome: Towards a Postgenomic Ethics of Germline Editing
Güttinger, S. (2019) · Journal of Applied Philosophy · doi:10.1111/japp.12367 · Cited by 11
Ethical and Legal Aspects of Using Genome Editing Technologies in Medicine (Review)
Karagyaur, M. N., Efimenko, A. Y., Макаревич, П. И., Vasiluev, P. A., Akopyan, Z. A., Брызгалина, Е., & Va, T. (2019) · Современные технологии в медицине · doi:10.17691/stm2019.11.3.16 · Cited by 11
Designing Preclinical Studies in Germline Gene Editing: Scientific and Ethical Aspects
Nordgren, A. (2019) · Journal of Bioethical Inquiry · doi:10.1007/s11673-019-09947-9 · Cited by 11
Germline genetic modification, CRSIPR, and human identity: Can genetics turn you into someone else?
Juth, N. (2016) · Ethics Medicine and Public Health · doi:10.1016/j.jemep.2016.05.003 · Cited by 11
What to Expect When Expecting CRISPR Baby Number Four
Scott, C. T., & Selin, C. L. (2019) · The American Journal of Bioethics · doi:10.1080/15265161.2018.1562793 · Cited by 11
Cohen, I. G. (2018) · Indiana Journal of Global Legal Studies · doi:10.2979/indjglolegstu.25.1.0439 · Cited by 10
Vogt, H. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0005 · Cited by 11
Genome editing of human embryos for research purposes: Japanese lay and expert attitudes
Akatsuka, K., Hatta, T., Sawai, T., & Fujita, M. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1205067 · Cited by 10
Nelson, J. P., Tomblin, D. C., Barbera, A., & Smallwood, M. (2023) · Public Understanding of Science · doi:10.1177/09636625231189955 · Cited by 10
The illusion of control in germline-engineering policy
König, H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3884 · Cited by 10
Zhang, J., Zhou, W., Wang, X., & Wang, L. (2018) · RSC Advances · doi:10.1039/c8ra04509g · Cited by 10
Emergent challenges for CRISPR: biosafety, biosecurity, patenting, and regulatory issues
Braddick, D., & Ramarohetra, R. F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818140-9.00021-0 · Cited by 10
Zehr, E. P. (2015) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2015.00072 · Cited by 10
Genome Editing with Crispr-Cas9 Systems: Basic Research and Clinical Applications
Meiliana, A., Dewi, N. M., & Wijaya, A. (2017) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v9i1.272 · Cited by 10
Life scientists’ views and perspectives on the regulation of dual-use research of concern
Engel, S., & Ienca, M. (2017) · Science and Public Policy · doi:10.1093/scipol/scx050 · Cited by 10
CRISPR—a challenge for national and international regulation
Nicol, D. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0014 · Cited by 9
A forecast for large-scale, predictive biology: Lessons from meteorology
Covert, M. W., Gillies, T. E., Kudo, T., & Agmon, E. (2021) · Cell Systems · doi:10.1016/j.cels.2021.05.014 · Cited by 9
Ethics Information Seeking and Sharing Among Scientists
Kahlor, L. A., Dudo, A. D., Liang, M.-C., Lazard, A. J., & AbiGhannam, N. (2015) · Science Communication · doi:10.1177/1075547015617942 · Cited by 9
What Is Prudent Governance of Human Genome Editing?
Schweikart, S. J. (2019) · The AMA Journal of Ethic · doi:10.1001/amajethics.2019.1042 · Cited by 9
Metadata
- Authors
- Baltimore, D., Berg, P., Botchan, M., Carroll, D., Charo, R. A., Church, G., Corn, J. E., Daley, G. Q., Doudna, J. A., Fenner, M., Greely, H. T., Jinek, M., Martin, G. S., Penhoet, E., Puck, J., Sternberg, S. H., Weissman, J. S., & Yamamoto, K. R.
- Affiliations
- California Institute of Technology (US)
- Stanford Medicine (US)
- Innovative Genomics Institute (US)
- University of Utah (US)
- University of Wisconsin–Madison (US)
- Harvard University (US)
- Boston Children's Hospital (US)
- Howard Hughes Medical Institute (US)
- Stanford University (US)
- Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
- University of California, Berkeley (US)
- Alta Partners, One Embarcadero Center, 37th Floor, San Francisco, CA 94111, USA.
- University of California, San Francisco (US)
- Corresponding author
- Doudna, Jennifer A.
- Venue
- Science
- Published
- 2015-04-03
- Volume
- 348
- Issue
- 6230
- Pages
- 36-38
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4394183
- OpenAlex
- W1987739153
- Cited by
- 733
- References
- 7
- Citations by year
- 2026: 37 · 2025: 28 · 2024: 48 · 2023: 34 · 2022: 52 · 2021: 46 · 2020: 77 · 2019: 74 · 2018: 75 · 2017: 96 · 2016: 80 · 2015: 84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Caribou Biosciences, Inc.
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics and bioethics in healthcare
- Keywords
- CRISPR/Cas9, germline editing, public discourse, genome editing regulation
- MeSH terms
- Biotechnology, Genetic Engineering, Germ Cells, Humans, Risk Management, Genome, Human, Genetic Predisposition to Disease, Gene Transfer, Horizontal, Genomics, Targeted Gene Repair, Clustered Regularly Interspaced Short Palindromic Repeats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
